Generic drug submission levels continued their yo-yo-like ride in fiscal year 2017, dropping substantially once again after an uptick, while FDA maintained its steady approval pace.
After a spike in March where nearly 200 ANDAs were sent to FDA, in April the agency reported receiving only...